I am of the belief that Leo et al thought that it was too early, prior to the RBL final reports of their B investigation and the advance release of the peer review article, for IPIX and Brilacidin to be making major waves in the mass media.

Just as a good sauce needs time to set up, so does what could be the "golden" answer to CV19. No need to rush, no need to bring about a broohaha as to whether it is the real deal, no need to get the public expecting it to be available prior to those issues already being resolved by further study.

The RBL results will speak for themselves, the human trial will be the final test to make sure B transfers from the lab to humans as expected, and IPIX will not come off looking as a small time startup trying to hype an untested drug but as a class act that let the government and other outside agencies collect the data to prove the worth of B.

This approach IMO is very professional and goes hand in hand with our PRs now coming across as much more professional.